Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15107755 | 0.81 | DRD2 (0.36) | DRD2DRD3ADRA2AADRA2BADRA2C | |
| SCHEMBL12731159 | 0.81 | DRD2 (0.36) | DRD2DRD3ADRA2AADRA2BADRA2C | |
| SCHEMBL14416074 | 0.81 | DRD2 (0.36) | DRD2DRD3ADRA2AADRA2BADRA2C | |
| SCHEMBL12237661 | 0.78 | DRD2 (0.34) | DRD2DRD3OPRL1CYP2D6 | |
| SCHEMBL18959591 | 0.75 | DRD3 (0.39) | DRD2DRD3ADRA2AADRA2BADRA2C | |
| SCHEMBL13267565 | 0.75 | DRD2 (0.33) | DRD2DRD3OPRL1 | |
| SCHEMBL8340387 | 0.74 | DRD3 (0.48) | DRD2DRD3OPRM1ADRA2AADRA2B | |
| SCHEMBL21555729 | 0.74 | ANPEP (0.40) | OPRD1OPRL1CXCR4CYP2D6CYP3A4 | |
| Hydrochloric Acid SCHEMBL17768575 | 0.72 | ANPEP (0.42) | OPRD1OPRL1CXCR4CYP2D6CYP3A4 | |
| SCHEMBL3838497 | 0.72 | KDM1A (0.43) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7041672-B2 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC. (US) | 2006-05-09 | — | — | US | disclosed |
| US-6992087-B2 | Substituted aryl 1,4-pyrazine derivatives | PFIZER INC (US) | 2006-01-31 | — | — | US | disclosed |
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | PFIZER INC | 2005-03-03 | — | — | US | disclosed |
| EP-1446387-A1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2004-08-18 | — | — | EP | disclosed |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | PHARMACIA & UPJOHN COMPANY | 2003-07-31 | — | — | US | disclosed |
| WO-2003045924-A1 | SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES | PHARMACIA & UPJOHN COMPANY (US) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049257-A1 | Substituted aryl 1, 4-pyrazine derivatives | HTR2C, HTR4, HTR5A | DRD2 33/4885DRD3 76/4885OPRM1 189/4885 |
| US-20030144297-A1 | Substituted aryl 1,4-pyrazine derivatives | HTR2C, HTR4, HTR5A | DRD2 33/4885DRD3 76/4885OPRM1 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.